Industry Analysis & Industry Trends
Get well
The necessary nature of cough and cold medicine will support stable industry growth, as people consistently contract viruses. Firms will continue to benefit from economies of scale, with profit margins remaining high. Nevertheless, healthcare reform will allow more people to have health insurance, resulting in more prescription drug sales in place of OTC medication. ... purchase to read more
Industry Report - Industry Key Buyers Chapter
The top four companies in the Cough and Cold Medicine Manufacturing OTC industry are estimated to make up 62.2% of total revenue in 2012. These companies are all diversified corporations, with substantial operations in other industries. The top four companies are Pfizer, Reckitt Benckiser, Johnson & Johnson and HIG Capital. The top three companies also produce other pharmaceuticals, helping them cut down per-unit production costs and develop brand awareness across categories. For example, Tylenol produces a number of subproducts, ranging from Tylenol Cold & Flu to Tylenol Arthritis Pain. HIG Capital acquired Matrixx Initiatives in 2011, and further acquisitions are expected in the industry as regulatory and marketing costs escalate... purchase to read more